(Q30304487)

16 June 2017

1 reference

title

The relationship between infliximab treatment and lymphoma in Crohn's disease (English)

1 reference

16 June 2017

0 references

Bickston SJ

1

1 reference

16 June 2017

Lichtenstein GR

2

1 reference

16 June 2017

Arseneau KO

3

1 reference

16 June 2017

Cohen RB

4

1 reference

16 June 2017

Cominelli F

5

1 reference

16 June 2017

language of work or name

English

0 references

publication date

1 December 1999

1 reference

16 June 2017

1 reference

16 June 2017

117

1 reference

16 June 2017

1433-1437

1 reference

16 June 2017

6

1 reference

Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference

16 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970294-5

Hodgkin's disease complicating Crohn's disease in a child.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970294-5

Primary Hodgkin disease of the ileum complicating Crohn disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970294-5

Primary intestinal Hodgkin's disease complicating ileal Crohn's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970294-5

Development of lymphoma in patients with Crohn disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970294-5

Crohn's disease and carcinoma of colon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970294-5

Hodgkin's lymphoma: a complication of small bowel Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970294-5

Primary malignant lymphoma of the large intestine complicating chronic inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970294-5

Extraintestinal cancers in inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970294-5

Adenocarcinoma and crohn's disease a report of 2 cases and analysis of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970294-5

Malignancy in Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970294-5

Lymphosarcoma in Crohn's disease: report of a case

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970294-5

Malignancy in Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970294-5

Malignant lymphoma, immunoblastic with plasmacytic differentiation, complicating Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970294-5

Lymphoma in inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970294-5

Reversible lymphoma in the setting of azathioprine therapy for Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970294-5

Ki-1-positive large cell lymphomas, a heterogenous group of neoplasms. Morphologic, immunophenotypic, genotypic, and clinical features of 24 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970294-5

Cancers complicating organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970294-5

Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970294-5

The mortality of rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970294-5

Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970294-5

Extracolonic malignancies in inflammatory bowel disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970294-5

6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970294-5

The tumor necrosis factor ligand and receptor families.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970294-5

Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970294-5

T-lymphocyte development and function in gene-targeted mutant mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970294-5

Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970294-5

10.1016/S0016-5085(99)70294-5

7 January 2021

Identifiers

DOI

1 reference

16 June 2017

1 reference